TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and perspectives. Mutat Res. 2005;589:192-207.de Moura Gallo CV, Azevedo ESMG, de Moraes E, Olivier M, Hainaut P. TP53 mutations as biomarkers for cancer epidemiology in Latin America: current knowledge and...
Mutations in the tumor suppressor gene TP53 have previously been described as a prognostic factor associated with worse outcome for a variety of different malignancies. In a recent Swedish study, Andersson and colleagues have investigated the TP53 gene, describing the prognosis and prognostic value of...
Because of the universal/almost universal dysfunction in malignancy, p53 is theoretically a highly attractive target against which to develop new anticancer treatments. The aim of this article is therefore to discuss the current status of pharmacological manipulation of p53 for the treatment of cancer,...
Therefore, characterisation of the impacts of different p53 mutant proteins is essential for improving the prognostic and predictive values of mutant p53 for treatment response, as well as for the development of personalised treatments for patients with p53 mutant lung cancers. Overall, p53 mutations ...
Compounds like APR-246, PK11007, and COTI-2 are promising treatments for patients with trible negative (TN) breast tumours because p53 is mutated in the great majority of them. However,mutant p53 can work as a biomarker in breast cancer, is not clearly defined [159]. Critical Outcome Techo...
Compounds like APR-246, PK11007, and COTI-2 are promising treatments for patients with trible negative (TN) breast tumours because p53 is mutated in the great majority of them. However,mutant p53 can work as a biomarker in breast cancer, is not clearly defined [159]. ...
for patients with advanced lung cancer and they have been shown to significantly improve patient survival. However, these treatments have substantial toxicity and the recurrence rate of malignant disease is still high [116]. Immunotherapy is a new modality for cancer therapy. Immune checkpoint ...
In vivo drug treatments 体内药物治疗 Para_01 肿瘤生长被监测,当原发性肿瘤可触及时开始进行药物治疗。 小鼠通过口服管饲法每天接受载体(0.1% 吐温 80/0.5% 羧甲基纤维素钠,100 μl),拉帕替尼(按体重计 100 mg/kg),AZD4547(按体重计 10 mg/kg)或拉帕替尼(按体重计 100 mg/kg)+ AZD4547(按体重计 ...
Our data imply that women with TP53-mutated breast cancer tumours should be offered treatments other than CMF. For example, Kandolier-Eckersberger et al. [29] indicate that patients with mutated TP53 might benefit from paclitaxel, while the response to FEC is dependent on wild type TP53, ...
century, which paved the way for radiation therapy combined with surgery, the field of oncology has witnessed a series of transformative treatments.Key developments include the introduction of chemotherapy during World War II, the advent of immunotherapy, and the more recent progress in gene therapy....